Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

Researchers analyze prostate cancer incidence over 20 years in men aged 45-70 years without prostate cancer and identify ...

Biochemical recurrence is when your PSA level starts to rise after finishing prostate cancer treatment, and it may sometimes indicate metastatic disease. Biochemical recurrence is a term for when your ...

Many men with low levels could be spared from invasive procedures and frequent testing ...

Prostate cancer is one of the most common cancers that occur in men. While it can be life-threatening, the disease is treatable, and the earlier it is detected, the better the treatment outcome.

After surgical removal of the prostate to treat prostate cancer, clinicians monitor Prostate Specific Antigen (PSA) levels. Persistently elevated PSA levels indicate residual cancer and are linked to ...

Hormone therapy initiation depends on disease extent; some agents avoid testosterone flare, allowing ADT without Casodex in certain cases. Active surveillance is increasingly chosen for favorable ...

High pre-treatment PSA levels correlate with increased recurrence and treatment failure in intermediate-risk prostate cancer patients treated with HIFU. Gleason grade 3 or higher is associated with ...